Idarucizumab

From WikiProjectMed
Jump to navigation Jump to search
Idarucizumab
Monoclonal antibody
TypeFab fragment
SourceHumanized (from mouse)
TargetDabigatran
Names
Trade namesPraxbind
Other namesBI-655075
Clinical data
Main usesReversal of dabigatran[1]
Side effectsHeadache, nausea, constipation[1]
Pregnancy
category
  • AU: B2
Routes of
use
Intravenous
Typical dose5 gram[1]
External links
AHFS/Drugs.comMonograph
US NLMIdarucizumab
Legal
License data
Legal status
Chemical and physical data
FormulaC2131H3299N555O671S11
Molar mass47782.71 g·mol−1

Idarucizumab, sold under the brand name Praxbind, is a medication used to reverse the effects of dabigatran.[1] Specifically it is used if severe bleeding or urgent surgery is required.[1] It is given by injection into a vein.[3]

Common side effects include headache, nausea, and constipation.[1] Severe side effects may include blood clots and allergic reactions.[1] It is a monoclonal antibody that works by binding to and inactivating dabigatran.[1][2]

Idarucizumab was approved for medical use in the United States and Europe in 2015.[1][2] In the United Kingdom it costs the NHS about £2,400 for a dose as of 2021.[3] This amount in the United States costs about 4,500 USD.[4]

Medical uses

Dabigatran can be started again once 24 hours has passed from this medication being given.[3]

Dosage

It is given as a dose of 5 gram.[1] Occasionally a second 5 gram dose may be used.[3]

Society and culture

Names

Idarucizumab is the International nonproprietary name (INN).[5] The description was updated in 2016.[6] Idarucizumab is the United States Adopted Name (USAN).[7]

See also

References

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 "Praxbind- idarucizumab injection". DailyMed. 1 December 2019. Retrieved 19 August 2020.
  2. 2.0 2.1 2.2 "Praxbind EPAR". European Medicines Agency (EMA). Retrieved 16 October 2020.
  3. 3.0 3.1 3.2 3.3 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 131. ISBN 978-0857114105.
  4. "Praxbind Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 25 November 2021.
  5. World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 71". WHO Drug Information. 28 (1): 90–91. hdl:10665/331151.
  6. World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76". WHO Drug Information. 30 (3): 544. hdl:10665/331020.
  7. Statement On A Nonproprietary Name Adopted By The USAN Council - Idarucizumab, American Medical Association.

External links

External sites:
Identifiers: